-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Engineering γδ T cells: A New Tool for Cancer Immunotherapy

Program: Spotlight Sessions
Session: Who are the Alternatives for Cellular Therapies? Engineering and Retargeting Other Effector Lymphocytes
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Biological therapies, Translational Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Therapies, Immunotherapy, emerging technologies, Technology and Procedures
Monday, December 11, 2023, 2:45 PM-4:00 PM

Jonathan P H Fisher

Cancer Section, UCL Great Ormond Street Institute of Child Health, London, ENG, United Kingdom

Disclosures: Fisher: Shattuck Labs: Consultancy, Membership on an entity's Board of Directors or advisory committees.

OffLabel Disclosure: The use of Zoledronic acid as a means of expanding or stimulating gamma-delta T cells may be discussed

See more of: Who are the Alternatives for Cellular Therapies? Engineering and Retargeting Other Effector Lymphocytes
See more of: Spotlight Sessions
<< Previous Presentation | Next Presentation